Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca blocks take-private buyout of Sobi

AstraZeneca blocks take-private buyout of Sobi

Mattias Haggblom, an analyst at Swedish bank Handelsbanken, said that its $39bn acquisition of Alexion this summer meant AstraZeneca had too much debt to acquire any of Sobi’s drugs in

Latest news

More from news
Approximately 41 fully matching, plus 33 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • What does the future hold for Light-chain Amyloidosis?

    Sanofi’s Isatuximab, and a potentially first-in-class fibril-reactive mAb from AstraZeneca’s Alexion division.

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

  • Mind+Matter Mind+Matter

    Our clients span the full spectrum of health – from deep pharma, to consumer health, healthy beauty and animal health.  They include: Aerogen,  Akcea,  Allakos, Alexion,  Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer,

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...